Abarelix Patent Expiration
Abarelix is used for treating advanced symptomatic prostate cancer in men. It was first introduced by Speciality European Pharma Ltd
Abarelix Patents
Given below is the list of patents protecting Abarelix, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Plenaxis | US5968895 | Pharmaceutical formulations for sustained drug delivery |
Dec 11, 2016
(Expired) | Speciality European |
| Plenaxis | US6180608 | Pharmaceutical formulations for sustained drug delivery |
Dec 11, 2016
(Expired) | Speciality European |
| Plenaxis | US6699833 | Pharmaceutical formulations for sustained drug delivery |
Dec 11, 2016
(Expired) | Speciality European |
| Plenaxis | US5843901 | LHRH antagonist peptides |
Dec 01, 2015
(Expired) | Speciality European |
| Plenaxis | US6423686 | LHRH antagonist peptides |
Jun 07, 2015
(Expired) | Speciality European |
| Plenaxis | US6455499 | Methods for treating disorders associated with LHRH activity |
Jun 07, 2015
(Expired) | Speciality European |
Abarelix's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List